Back |
home / stock / cmpx / cmpx message board
Subject | By | Source | When |
---|---|---|---|
B of A health conf went great | marketmanallm | investorshub | 05/16/2022 3:46:15 PM |
More insider buys and nice names involved.Love this sleeper | marketmanallm | investorshub | 05/11/2022 2:21:53 PM |
I like this stock .10 ct downside 5 | marketmanallm | investorshub | 05/06/2022 12:44:07 PM |
4 previous posts (to qualify as a board moderator). | wiredawg | investorshub | 11/10/2021 1:34:38 PM |
https://www.compasstherapeutics.com/press-releases/compass-therapeutics-to-comme | wiredawg | investorshub | 11/10/2021 1:23:39 PM |
https://www.compasstherapeutics.com/press-releases/compass-reports-the-advanceme | wiredawg | investorshub | 11/10/2021 1:21:31 PM |
https://www.compasstherapeutics.com/press-releases/compass-therapeutics-announce | wiredawg | investorshub | 11/10/2021 1:20:35 PM |
ALRIGHT $NOW!!! A first for me to be | wiredawg | investorshub | 11/10/2021 1:18:32 PM |
News, Short Squeeze, Breakout and More Instantly...
Compass Therapeutics Inc. Company Name:
CMPX Stock Symbol:
OTCMKTS Market:
Compass Therapeutics Inc. Website:
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside cha...
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Sc...
CTX-471, a novel anti-CD137 agonist antibody, demonstrated anti-tumor activity in the Company’s Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors....